Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WEE1 small interfering RNA
- Development stage
- Preclinical
- Lead developer
- National Cancer Institute
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Topical
01
Overview
WEE1 small interfering RNA is an RNA interference (RNAi) therapeutic designed to silence the expression of the WEE1 kinase. WEE1 is a key regulator of the G2/M cell cycle checkpoint, preventing cells with DNA damage from entering mitosis. In cancers like diffuse pleural mesothelioma (DPM), WEE1 is often overexpressed. Silencing WEE1, particularly in combination with other cell cycle regulators like PKMYT1, induces synthetic lethality by forcing cells into premature mitosis with unrepaired DNA damage, leading to apoptosis. This specific siRNA is being evaluated by researchers at the National Cancer Institute (NCI) within a nanoparticle-hydrogel delivery platform for localized treatment of anatomically restricted cancers.
- Other names
- WEE1 siRNAWEE-1 siRNAWEE 1 siRNA
02
Targets
WEE1 (WEE1 G2 checkpoint kinase)
Beyond the preview
Go deeper on WEE1 small interfering RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WEE1 small interfering RNA.